GenSight Biologics, the Paris-based clinical-stage biopharma company focused on gene therapies for retinal neurodegenerative diseases, has administered lenadogene nolparvovec (GS010) to the first cohort of patients enrolled in France’s Named Patient Early Access Program (Autorisation d’Acces Compassionnel, or AAC) for Leber Hereditary Optic Neuropathy caused by the ND4 mitochondrial gene mutation. Treatments were delivered at the 15-20 National Hospital in Paris on March 19, 2026, under authorisation from the French medicines safety agency ANSM, while the company’s parallel Phase II REVISE dose-ranging study has now enrolled four patients since its February 2026 start.
Why the AAC pathway matters for a disease with no approved standard of care
ND4-LHON leaves clinicians with almost nothing to offer. The condition causes rapid, typically permanent loss of central vision in adolescents and young adults, driven by the degeneration of retinal ganglion cells whose loss is largely irreversible once the acute phase has passed. The narrow treatment window is clinically decisive: retinal ganglion cells that survive the initial insult can potentially be rescued by gene supplementation, while those already lost cannot. For a disease this time-sensitive, any gap between regulatory approval and patient access carries consequences measured in degrees of permanent blindness. The AAC framework is France’s mechanism for bridging exactly that gap. It permits treatment outside of a clinical trial when a serious or rare condition lacks an appropriate approved therapy and when early data suggest a plausible benefit-risk profile. GenSight Biologics first reached agreement with ANSM on the AAC pathway in mid-2025, following a period of negotiation that also established the requirement for the REVISE dose-ranging study as a parallel regulatory condition. The first individual named patient applications were submitted in February 2026 and approved by ANSM on March 9. Actual treatments followed ten days later, suggesting the administrative processing cycle is shorter than many comparable access programs in other jurisdictions.
What the REVISE study is designed to resolve and why ANSM required it
The REVISE study is a dose-ranging Phase II trial, authorised by ANSM and the relevant Ethics Committee in December 2025. Its central purpose is to compare at least two doses of lenadogene nolparvovec, generating data that the regulator requires before it can evaluate a broader marketing authorisation. The fact that ANSM imposed REVISE as a condition of the AAC program is itself analytically significant. It signals that the agency, while accepting the drug’s early clinical evidence as sufficient grounds for compassionate access, does not consider the existing Phase III data package complete enough to support a conventional dossier without further dose optimisation evidence. This is a relatively common position for rare disease gene therapies in Europe, where regulators have grown more cautious about the scalability of early-phase results, particularly where viral vector gene therapies involve irreversible interventions and limited redosing options.
The existing Phase III data for lenadogene nolparvovec, generated across the RESCUE and REVERSE trials and their long-term follow-up studies, showed a bilateral benefit even when only one eye received the active treatment, a finding attributed to a contralateral diffusion effect of the AAV2 vector. However, those trials used a fixed dose. Whether a lower dose achieves comparable efficacy with a better safety profile, or whether a higher dose confers meaningfully greater neuroprotection, remains unanswered. REVISE is designed to provide that answer, and its data will almost certainly form the centrepiece of any future marketing authorisation submission to the European Medicines Agency. Industry observers tracking rare disease ophthalmology note that dose-ranging evidence is increasingly expected by European regulators even for gene therapies with compelling proof-of-concept data, because the irreversibility of the intervention raises the stakes of suboptimal dosing considerably.
How the dual-track model balances patient access with data generation requirements
Running the AAC program and the REVISE study simultaneously creates an unusual regulatory architecture. Patients who are eligible for both pathways are directed first to the clinical trial, consistent with applicable French regulations prioritising data generation over compassionate access where enrolment is feasible. Those who cannot enrol in REVISE, whether due to clinical contraindications, geographic barriers, or capacity constraints, become candidates for the AAC program. This design prevents the access program from undermining enrolment in the study, a tension that has historically plagued compassionate use frameworks in rare diseases where patient populations are small. The structure is pragmatically sound but introduces a risk of fragmentation: patients treated under the AAC program will not contribute rigorous comparative data, which means the company’s evidence base for regulatory submissions remains dependent on REVISE enrolment running to plan. Any disruption to REVISE timelines, including supply constraints, site capacity issues, or slow patient identification, would not be offset by the AAC treatment volume.
Manufacturing transition and supply risk underlying both programs
Supply is not a background consideration for GenSight Biologics; it is an active operational variable. The company completed a technology transfer to Catalent as its new manufacturing partner in late 2025, a transition that was necessary to enable the production of fresh batches capable of supporting both REVISE and AAC demand through 2026. Gene therapy manufacturing, particularly with AAV vectors, is technically demanding and batch-yield variability is an inherent risk. Any shortfall in Catalent’s production capacity or a batch failure would directly constrain the number of patients that can be treated under either pathway. The 15-20 National Hospital’s clinical teams are described as fully mobilised for both programs, meaning the bottleneck is less likely to be clinical capacity than product supply. Regulatory watchers following the gene therapy sector note that the Catalent partnership remains an unverified dependency at this stage, with the company yet to publicly confirm that commercial-scale batches from the new facility have cleared all release testing criteria.
The financial dimension: early access revenues as a survival mechanism
The timing of the first AAC treatments carries a financial dimension that cannot be separated from the clinical narrative. GenSight Biologics disclosed in early 2026 that its cash runway would not extend beyond February 2026 without additional revenue or financing. The company indicated in March 2026 that early access program revenues, taken in aggregate across France and the United States, are expected to be sufficient to ensure operational continuity through 2026, with first payments from the French AAC program expected before the end of March. This means the clinical milestone announced on March 19 is simultaneously a corporate survival event. For a company of this size and stage, that is not unusual in the gene therapy space, but it does create an incentive structure in which the pace of patient access is financially as well as clinically motivated. Industry observers note that companies reliant on compassionate use revenues to fund ongoing clinical operations face a specific tension: pressure to maximise access program volume can occasionally conflict with the regulatory discipline required to maintain a clean trial protocol.
What US expanded access activity reveals about the broader strategy
In parallel with the French programs, GenSight Biologics has been advancing individual patient expanded access in the United States through the FDA’s single patient Investigational New Drug mechanism. A second US patient was cleared for treatment in January 2026 following the FDA’s approval of a single patient IND, coming after the treatment of an initial US patient whose IND was cleared in October 2025. The US program does not involve the same kind of structured compassionate access framework as the French AAC, and each case requires individual FDA authorisation, making meaningful volume unlikely in 2026. The company’s out-licensing strategy for markets outside the US and Europe adds a third revenue and access dimension. If those negotiations advance, they would extend the patient reach of lenadogene nolparvovec without requiring direct commercial investment from GenSight Biologics, though the timelines for any such arrangements remain unclear.
Unresolved questions for clinicians and regulators watching this program
Several questions will define the next twelve months for lenadogene nolparvovec. Whether REVISE enrols on schedule and whether it generates dose-differentiated efficacy signals will determine the company’s ability to pursue a European marketing authorisation. Whether the Catalent manufacturing relationship produces reliable, release-qualified supply will determine the scale of access under both pathways. Whether the Phase III RECOVER study launches as planned in the second half of 2026 will signal whether GenSight Biologics has secured the additional financing it has indicated it will continue to pursue on both dilutive and non-dilutive terms. And whether the AAC patient outcomes align with what was observed in the Phase III program will carry real-world validation weight for any future regulatory submission. For a gene therapy treating an irreversible condition in young patients with no alternatives, the stakes of getting any of these variables wrong are unusually high.
GenSight Biologics begins LHON treatment under France compassionate access as REVISE Phase II moves forward added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →